54,528 Bristol Myers Squibb Company $BMY Shares Sold by Curated Wealth Partners LLC

Curated Wealth Partners LLC lowered its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 67.2% in the third quarter, Holdings Channel reports. The institutional investor owned 26,635 shares of the biopharmaceutical company’s stock after selling 54,528 shares during the quarter. Curated Wealth Partners LLC’s holdings in Bristol Myers Squibb were worth $1,662,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in BMY. Primecap Management Co. CA acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $1,436,115,000. Legal & General Group Plc acquired a new stake in shares of Bristol Myers Squibb in the second quarter worth about $980,862,000. BlackRock Inc. raised its stake in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. State Street Corp raised its stake in shares of Bristol Myers Squibb by 7.3% in the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after acquiring an additional 7,192,724 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in Bristol Myers Squibb by 153.8% during the first quarter. SG Americas Securities LLC now owns 8,910,032 shares of the biopharmaceutical company’s stock worth $540,393,000 after purchasing an additional 5,399,407 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers reported encouraging Phase 3 data for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, including an improvement in progression-free survival. The results could support upcoming regulatory discussions and strengthen the company’s oncology pipeline. What Could Bristol Myers Squibb Two Phase 3 Wins Change?
• Positive Sentiment: Additional late-stage results for admilparant in idiopathic pulmonary fibrosis were described as showing meaningful clinical benefits and a favorable safety profile. If confirmed, the program could add a new growth opportunity beyond Bristol Myers’ established products. Phase 3 Wins
• Positive Sentiment: Truist maintained a Buy rating, while several articles highlighted BMY’s relatively modest valuation, income potential and history of maintaining dividends through difficult market conditions. Its valuation metrics include a P/E near 13.5 and a PEG ratio below 0.3. Truist Buy Rating
• Neutral Sentiment: BMY became a heavily searched or “trending” stock on Zacks, increasing visibility but providing no fundamental change by itself. Analysts’ opinions remain mixed across comparisons with other healthcare companies. Trending Stock Analysis
• Negative Sentiment: Other coverage characterized the admilparant Phase 3 results as mixed, creating uncertainty about the drug’s ultimate approval prospects and commercial contribution. Investors must also weigh long-term patent expirations and competition affecting blockbuster medicines. Mixed Phase 3 Trial Results

Bristol Myers Squibb Trading Up 3.1%

Bristol Myers Squibb stock traded up $1.83 during midday trading on Thursday, hitting $61.11. 5,578,121 shares of the stock were exchanged, compared to its average volume of 12,057,397. The stock has a market capitalization of $124.83 billion, a PE ratio of 13.46, a P/E/G ratio of 0.28 and a beta of 0.19. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The company has a fifty day simple moving average of $63.72 and a two-hundred day simple moving average of $60.28. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.70 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s payout ratio is currently 55.51%.

Analysts Set New Price Targets

BMY has been the subject of a number of analyst reports. Bank of America reduced their price objective on shares of Bristol Myers Squibb from $71.00 to $66.00 in a research note on Friday, October 9th. Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Cantor Fitzgerald decreased their price target on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a research note on Thursday, October 8th. Roth Capital started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price objective for the company. Finally, JPMorgan Chase & Co. increased their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $64.88.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.